

### **In the Claims**

1. (Original) A polynucleotide comprising the nucleotide sequence shown in SEQ ID NO: 2 or a part thereof.
2. (Currently Amended) A polynucleotide comprising a nucleotide sequence shown in SEQ ID NO: 2, in which one or [a few] more nucleotides are deleted, substituted, or added, comprising a nucleotide sequence contained in the nucleotide sequence of the sense strand of the PDGF receptor ~~alfa~~ alpha gene or a part thereof.
3. (Currently Amended) A polynucleotide comprising a nucleotide sequence complementary to the polynucleotide or part thereof of claim 1[ or 2].
4. (Currently Amended)) A method for suppressing expression of PDGF receptor ~~alfa~~ alpha comprising targeting mRNA including exon 1 beta among mRNAs of the PDGF receptor ~~alfa~~ alpha gene.
5. (Original) The method of claim 4, wherein antisense nucleotides, a ribozyme, a maxizyme, or an RNAi is used.
6. (Original) The method of claim 4, wherein DNA that encodes an antisense RNA, a ribozyme, a maxizyme, or an RNAi is used.
7. (Currently Amended) A substance for suppressing expression of PDGF receptor-~~alfa~~ alpha comprising targeting mRNA containing exon 1 beta among mRNAs of the PDGF receptor ~~alfa~~ alpha gene.
8. (Original) The substance of claim 7, which is antisense nucleotides, a ribozyme, a maxizyme, or an RNAi.
9. (Original) The substance of claim 7, which is a DNA that encodes an antisense RNA, a ribozyme, a maxizyme, or an RNAi.

10. (Currently Amended) An agent for suppressing expression of PDGF receptor ~~alfa~~ alpha comprising the substance of claim 7 as an active ingredient.

11. (Original) A therapeutic agent for cancer comprising the agent of claim 10.

12. (Original) A therapeutic method for cancer, wherein the agent of claim 10 is used.

13. (New) A polynucleotide comprising a nucleotide sequence complementary to the polynucleotide or part thereof of claim 2.